MAPT and Alzheimer disease: Therefore, SSRIs and pimavanserin might exert neuroprotective effects in AD-related neurodegeneration, at least partially by regulating mitochondrial function, autophagy, synaptic function, as well as the amyloid- and tau-related pathways, paving the way for future research in MBI and related cognitive decline.